$VPRO .0043 Going, Ran Trips to .20+ Huge DD Multi Dollar

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
$VPRO .0043 Going, Ran Trips to .20+ Huge DD Multi Dollar Value, New Management, New Website & Huge Products

Partners are Big

BRI Biopharmaceutical Research http://www.bripharm.com

CoreRX Pharma
http://www.corerxpharma.com

Spectrum Pharmaceutical Inc. $7.00+ on Nasdaq
http://www.sppirx.com

Oncobiologics
http://www.oncobiologics.com

Alpha Biologics
http://www.alphabiologics.com

Huge Documents Involving Gilead, Celgene, Amgen, Biogene Idec and So Many Top Pharmaceuticals...VIROPRO is a Steal considering the Competitor's Value.... 73 Page Pharmaceutical & Biotechnology 2014 Outlook >> https://www.google.ca/url?sa=t&source=web...7CmJfnK8QA

New Website >> http://www.viropro.net

Active SOS >> https://nvsos.gov/sosentitysearch/CorpDetails...amp;nt7=0j

Outstanding Shares 916,000,000

Float 39,000,000

Insiders Holdings 48,000,000

Institutional Holdings 631,000,000

INSTITUTIONAL HOLDINGS

Spring Hill Bioventures Sdn Bhd
340,000,000

THG Capital Sdn Bhd
184,000,000

Intas Biopharmaceuticals Ltd.
106,916,666    

Employees

The Company has 34 employees.  Two of the employees are Viropro’s senior executive officers and seven are employees of BPD.  Under Alpha Biologics, there are 20 employees in Penang, Malaysia and 5 in Cambridge, UK.

Portfolio Valuation

Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products.

Projected Revenues

The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60–$150 million for Viropro within 10 years. The partnership is planning to launch its first product by late 2014.

The products include biosimilar version of Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (trastuzumab), Humira (adalimumab), Rituxan (rituximab) and a non-disclosed biological used for cancer and immune-disease indications.

New Management with Absolutely Huge Portfolios as of 2014

http://www.viropro.net/leadership-team/

The Board appointed Dr. Joseph J. Vallner as Acting President and Bruce A. Cohen as Chairman of the Board. Since 2009 Dr. Vallner has served as a consultant primarily to small pharmas/biotech companies and was previously President of ORUUS Pharma, a cancer drug delivery company, Lumera Corp., a company that developed products for electro-optics applications, which was a publicly traded company on NASDAQ during the time Dr. Vallner was its President and CEO, and President and CEO of Capnia, a company that developed nasal delivery of therapeutic gas for migraine and other inflammation disorders. Dr. Vallner received his BS degree in Pharmacy, his MS degree in hysical Chemistry and his PhD in Pharmaceutics (Biochemistry minor) from the University of Wisconsin. The Board is negotiating an employment agreement with Dr. Vallner.
 
Bruce A. Cohen has served as founding President and CEO of several biotech companies and assisted them with financings, including Vitapath Genetics, Inc. from 2008-2012, a personalized genetics company, Cellerant Therapeutics, Inc., from 2002-2007, a stem cell therapy company, and Acacia Biosciences, Inc. from 1997-2000, a bioinformatics-based functional genomics discovery company. Mr. Cohen was CFO of GeneSoft Pharmaceuticals from 2000-2001 and Vice President at SEQUUS Pharmaceuticals, Inc. from 1995-1997, a pharma company involved with liposome-based oncology and anti-infective drugs. Prior to these executive roles, Mr. Cohen was the President and COO of ViTel International and a management consultant with Monitor Company. Mr. Cohen has an MBA with distinction from Harvard Business School, and a BA and MA from Tufts University.


Viropro, Inc. and Oncobiologics, Inc. have signed a biosimilar collaboration agreement, under which Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging markets (excluding China).

Viropro will have commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Alpha Biologics biomanufacturing subsidiary in Penang, Malaysia.   

The biosimilars are generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux, and one other non-disclosed biotherapeutic. The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue rate of $60–$150 million in 10 years. The partnership plans to launch its first product by late 2014.

Competitors Capitalization

Lonza Group AG  (SWX:LONN)
$3.2 billion

Pharmaceutical Product Development, Inc. (Nasadaq PDI)
$3.8 billion

Cambrex Corporation (NYSE:CBM)
$210 million

Bioanalytical Systems, Inc. (Nasdaq:BASI)
$7.1 million

Viropro,Inc. (PINK :VPRO)
$2 million
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 76

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 33

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 79

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
DPR’s Parent Benefits Signal a Tougher Labor Market

Updated Category News Views 34

Concrete Schedules Do Not Bend Easily A jobsite does not care that daycare closes at 6 p.m., and that is exactly why DPR Construction’s latest workplace recognition deserves a closer look. The privately held, employee-owned contractor landed at No. 29 among large companies on the 2026 Fortune Best Workplaces for Parents list. It is not a quarterly earnings event, and...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 87

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 39

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 16

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading
Chipotle's Thanksgiving BOGO Tests Loyalty Muscle Again

Updated Category News Views 35

Thanksgiving Eve is a peculiar little battlefield for restaurant chains: everybody wants the reunion crowd, nobody wants to give away the register. Chipotle is stepping back into it on Wednesday, November 25, with its Back Home BOGO for Rewards members from 5 to 9 p.m. local time at participating U.S. restaurants. Buy an entrée in person, scan the Rewards account, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Foreign Real Estate: Navigating Ownership Laws for Profit

Updated Category Real Estate Views 1010

Foreign real estate offers tangible assets with strong returns for regular investors looking for diversification beyond stocks and cryptocurrency. Opportunities emerge in high-yield markets like Abu Dhabi, Singapore, Indonesia, Panama, and Greece; yet, making the most of these markets requires expert navigation of ownership regulations. It is important to be knowledgeable...

Continue Reading
Quisitive Technology Solutions Unveils Earnings Call Details

Updated Category News Views 151

Quisitive Schedules Earnings Call for Quarter Results Quisitive Technology Solutions, Inc. has announced that it will hold an earnings call to discuss its financial performance for the third quarter. This anticipated event is set for a Monday afternoon, specifically at 5:00 p.m. Eastern time. Relevant financial outcomes for the quarter ending September 30 will be...

Continue Reading
Exploring the Future of Speech and Voice Recognition Growth

Updated Category News Views 238

Insights into the Speech and Voice Recognition Market The Speech and Voice Recognition market has experienced remarkable growth, and analysts predict it will expand significantly in the coming years. Currently valued at around USD 12.63 billion, it's on a trajectory to reach an impressive USD 92.08 billion by 2032, reflecting a remarkable compound annual growth rate...

Continue Reading
Investors Must be Aware of Rights for Transocean Ltd. Shares

Updated Category News Views 231

Understand Your Rights as a Shareholder in Transocean Ltd. Shareholders of Transocean Ltd. (NYSE: RIG) should take a proactive approach regarding their investment and potential class actions. If you purchased shares between specific dates, it is crucial to stay informed about your rights and any actions you may need to take to protect your interests. What to Know About...

Continue Reading
JELD-WEN's 2025 Results: Disappearing Revenues and Grim Outlook

Updated Category News Views 286

JELD-WEN (NYSE:JELD) just dropped its fourth quarter and full year 2025 numbers, and let me tell you, traders are not feeling warm and fuzzy right now. Net revenues for Q4 came in at $802 million, a staggering decrease of 10.5% from the previous year. This is bad—real bad. Core revenues took an even worse hit with an 8% drop, compounded by a divestiture loss from...

Continue Reading